[go: up one dir, main page]

MX2019005379A - Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo. - Google Patents

Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo.

Info

Publication number
MX2019005379A
MX2019005379A MX2019005379A MX2019005379A MX2019005379A MX 2019005379 A MX2019005379 A MX 2019005379A MX 2019005379 A MX2019005379 A MX 2019005379A MX 2019005379 A MX2019005379 A MX 2019005379A MX 2019005379 A MX2019005379 A MX 2019005379A
Authority
MX
Mexico
Prior art keywords
preparation
pyrazolo
medical use
heteroaryl derivative
derivative
Prior art date
Application number
MX2019005379A
Other languages
English (en)
Other versions
MX391180B (es
Inventor
He Feng
Tao Weikang
Hu Qiyue
Zhang Guobao
Shu Chunfeng
Original Assignee
Jiangsu Hengrui Medicine Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co filed Critical Jiangsu Hengrui Medicine Co
Publication of MX2019005379A publication Critical patent/MX2019005379A/es
Publication of MX391180B publication Critical patent/MX391180B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se describen un derivado de pirazolo-heteroarilo, un método de preparación y su uso médico. En particular, la presente invención se refiere a un nuevo derivado de pirazolo-heteroarilo como el mostrado en la fórmula general (I), a un método de preparación del mismo y a una composición farmacéutica que contiene el derivado y a su uso como agente terapéutico, en particular como agonista de TLR7, en donde cada sustituyente en la fórmula general (I) se define en la descripción.
MX2019005379A 2016-11-28 2017-11-27 Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo MX391180B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201611066071 2016-11-28
PCT/CN2017/113007 WO2018095426A1 (zh) 2016-11-28 2017-11-27 吡唑并杂芳基类衍生物、其制备方法及其在医药上的应用

Publications (2)

Publication Number Publication Date
MX2019005379A true MX2019005379A (es) 2019-09-04
MX391180B MX391180B (es) 2025-03-21

Family

ID=62194797

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019005379A MX391180B (es) 2016-11-28 2017-11-27 Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo

Country Status (16)

Country Link
US (2) US11117898B2 (es)
EP (1) EP3546457B1 (es)
JP (1) JP7145854B2 (es)
KR (1) KR20190084991A (es)
CN (1) CN108884092B (es)
AU (1) AU2017366621B2 (es)
BR (1) BR112019010182A2 (es)
CA (1) CA3044903A1 (es)
ES (1) ES2886973T3 (es)
HU (1) HUE054964T2 (es)
MX (1) MX391180B (es)
MY (1) MY192084A (es)
PT (1) PT3546457T (es)
RU (1) RU2748833C2 (es)
TW (1) TWI760390B (es)
WO (1) WO2018095426A1 (es)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL265921B2 (en) 2016-10-14 2024-05-01 Prec Biosciences Inc Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome
AU2018392213B2 (en) 2017-12-20 2021-03-04 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein
KR102492115B1 (ko) 2017-12-20 2023-01-27 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. Sting 어댑터 단백질을 활성화하는 포스포네이트 결합을 가진 2'3' 사이클릭 다이뉴클레오티드
JP7050165B2 (ja) 2018-02-26 2022-04-07 ギリアード サイエンシーズ， インコーポレイテッド Ｈｂｖ複製阻害剤としての置換ピロリジン化合物
WO2019195181A1 (en) 2018-04-05 2019-10-10 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis b virus protein x
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 ２，２，─環二核苷酸
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
US11142750B2 (en) 2018-04-12 2021-10-12 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
WO2019209811A1 (en) 2018-04-24 2019-10-31 Bristol-Myers Squibb Company Macrocyclic toll-like receptor 7 (tlr7) agonists
WO2019211799A1 (en) 2018-05-03 2019-11-07 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide
CN110526918B (zh) * 2018-05-25 2021-09-03 江苏恒瑞医药股份有限公司 一种吡唑并杂芳基类衍生物的晶型及制备方法
JP2021526520A (ja) * 2018-05-25 2021-10-07 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司Ｊｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．， Ｌｔｄ． ピラゾロヘテロアリール誘導体の塩酸塩の結晶形および調製方法
CN110526917B (zh) * 2018-05-25 2021-09-03 江苏恒瑞医药股份有限公司 一种吡唑并杂芳基类衍生物的可药用盐、晶型及其制备方法
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
US11554120B2 (en) * 2018-08-03 2023-01-17 Bristol-Myers Squibb Company 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor
CN112512579B (zh) * 2018-09-29 2024-05-17 江苏恒瑞医药股份有限公司 Tlr激动剂与免疫检查点抑制剂联合在制备治疗肿瘤的药物中的用途
WO2020073942A1 (zh) * 2018-10-11 2020-04-16 江苏恒瑞医药股份有限公司 一种tlr7激动剂前药、其制备方法及其在医药上的应用
AU2019372046B2 (en) 2018-10-31 2022-05-26 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as HPK1 inhibitors
EP3873608A1 (en) 2018-10-31 2021-09-08 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
JP7564112B2 (ja) 2019-02-07 2024-10-08 ベイジーン リミテッド ＴＬＲ７アゴニストとしてのイミダゾ［２，１－ｆ］［１，２，４］トリアジン－４－アミン誘導体
JP7287708B2 (ja) 2019-02-08 2023-06-06 プロジェニア インコーポレイテッド Ｔｏｌｌ－ｌｉｋｅ受容体７または８アゴニストとコレステロールの結合体およびその用途
EP3935065A1 (en) 2019-03-07 2022-01-12 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
US12318403B2 (en) 2019-03-07 2025-06-03 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2′3′-cyclic dinucleotides and prodrugs thereof
JP7350872B2 (ja) 2019-03-07 2023-09-26 インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． ３’３’－環状ジヌクレオチドおよびそのプロドラッグ
TWI751516B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
WO2020237025A1 (en) 2019-05-23 2020-11-26 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
CN112007034B (zh) * 2019-05-31 2022-05-24 江苏恒瑞医药股份有限公司 Tlr激动剂与免疫检查点抑制剂、vegfr抑制剂联合在制备治疗肿瘤药物中的用途
WO2020259667A1 (zh) * 2019-06-28 2020-12-30 江苏恒瑞医药股份有限公司 Tlr激动剂与抗ox40抗体或其抗原结合片段联合在制备治疗肿瘤的药物中的用途
WO2021034804A1 (en) 2019-08-19 2021-02-25 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
KR20220074917A (ko) 2019-09-30 2022-06-03 길리애드 사이언시즈, 인코포레이티드 Hbv 백신 및 hbv를 치료하는 방법
CN112830929B (zh) * 2019-11-22 2022-09-16 江苏恒瑞医药股份有限公司 吡唑并杂芳基类化合物的制备方法
CN116057068A (zh) 2019-12-06 2023-05-02 精密生物科学公司 对乙型肝炎病毒基因组中的识别序列具有特异性的优化的工程化大范围核酸酶
WO2021154663A1 (en) * 2020-01-27 2021-08-05 Bristol-Myers Squibb Company 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
JP7684316B2 (ja) * 2020-01-27 2025-05-27 ブリストル－マイヤーズ スクイブ カンパニー トール様受容体７（ＴＬＲ７）アゴニストとしての１Ｈ－ピラゾロ［４，３－ｄ］ピリミジン化合物
KR20220132601A (ko) * 2020-01-27 2022-09-30 브리스톨-마이어스 스큅 컴퍼니 톨-유사 수용체 7 (TLR7) 효능제로서의 1H-피라졸로[4,3-d]피리미딘 화합물
US20230127326A1 (en) * 2020-01-27 2023-04-27 Bristol-Myers Squibb Company C3-SUBSTITUTED 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
JP2023512206A (ja) * 2020-01-27 2023-03-24 ブリストル－マイヤーズ スクイブ カンパニー トール様受容体７（ＴＬＲ７）アゴニストとしての１Ｈ－ピラゾロ［４，３－ｄ］ピリミジン化合物
JP2023512208A (ja) * 2020-01-27 2023-03-24 ブリストル－マイヤーズ スクイブ カンパニー トール様受容体７（ＴＬＲ７）アゴニストとしての１Ｈ－ピラゾロ［４，３－ｄ］ピリミジン化合物
US20230140430A1 (en) * 2020-01-27 2023-05-04 Bristol-Myers Squibb Company 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
US12485123B2 (en) 2020-01-27 2025-12-02 Bristol-Myers Squibb Company 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists
CN115210236A (zh) * 2020-01-27 2022-10-18 百时美施贵宝公司 作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物
US20230100429A1 (en) 2020-03-02 2023-03-30 Progeneer Inc. Live-pathogen-mimetic nanoparticles based on pathogen cell wall skeleton, and production method thereof
AU2021237718B2 (en) 2020-03-20 2023-09-21 Gilead Sciences, Inc. Prodrugs of 4'-C-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
CN113801136B (zh) * 2020-06-16 2023-04-07 江苏恒瑞医药股份有限公司 咪唑并杂芳基类衍生物、其制备方法及其在医药上的应用
WO2022031011A1 (ko) 2020-08-04 2022-02-10 성균관대학교산학협력단 동력학적으로 작용하는 아주번트 앙상블
US20230277525A1 (en) 2020-08-04 2023-09-07 Progeneer Inc Conjugate of functional drug and toll-like receptor 7 or 8 agonist of which active site is temporarily inactivated and use thereof
EP4194006A4 (en) 2020-08-04 2024-12-04 Progeneer Inc. mRNA VACCINE WITH AN ADJUVANT CAPABLE OF KINETIC CONTROL
CN114276351B (zh) * 2020-09-27 2023-06-16 江苏恒瑞医药股份有限公司 含氮杂环类衍生物、其制备方法及其在医药上的应用
CN114621230B (zh) * 2020-12-10 2023-06-16 江苏恒瑞医药股份有限公司 含氮杂环化合物、其制备方法及其在医药上的应用
JP2024518558A (ja) 2021-05-13 2024-05-01 ギリアード サイエンシーズ， インコーポレイテッド ＴＬＲ８調節化合物と抗ＨＢＶ ｓｉＲＮＡ治療薬との組合せ
CA3220923A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
EP4359413A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CN117377671A (zh) 2021-06-23 2024-01-09 吉利德科学公司 二酰基甘油激酶调节化合物
CN117355531A (zh) 2021-06-23 2024-01-05 吉利德科学公司 二酰基甘油激酶调节化合物
JP2024545185A (ja) * 2021-12-08 2024-12-05 シャンハイ ヴィソンファーマ カンパニー，リミテッド ＴＬＲ７／８作動剤としてのピリド［４，３－ｄ］ピリミジン系化合物
CN119604504A (zh) * 2022-09-16 2025-03-11 四川科伦博泰生物医药股份有限公司 一类双并环化合物、其制备方法及用途
CN119367281A (zh) * 2023-07-27 2025-01-28 苏州申拓医药科技有限公司 一种tlr7/8激动剂注射剂、其制备方法及其用途
CN119431359A (zh) * 2023-07-28 2025-02-14 苏州申拓医药科技有限公司 一种tlr7/8激动剂的可药用盐、晶型及其制备方法、药物组合物和用途
US20250345390A1 (en) 2024-05-13 2025-11-13 Gilead Sciences, Inc. Combination therapies
US20250345389A1 (en) 2024-05-13 2025-11-13 Gilead Sciences, Inc. Combination therapies
WO2025240246A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
WO2025240242A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6638967B2 (en) 2000-08-08 2003-10-28 Ortho-Mcneil Phamraceutical, Inc. Thiophene of furan pyrrolidine compounds
EA200600540A1 (ru) 2003-09-05 2006-08-25 Анадис Фармасьютикалз, Инк. Введение лигандов tlr7 и их пролекарств для лечения инфекции вируса гепатита с
JP2008538776A (ja) * 2005-04-25 2008-11-06 ノバルティス アクチエンゲゼルシャフト ペプチド脱ホルミル酵素（ｐｄｆ）阻害剤として有用なイミダゾ［１，２−ａ］ピリジン誘導体
ES2374455T3 (es) 2006-02-17 2012-02-16 Pfizer Limited Derivados de 3-deazapurinza como moduladores de tlr7.
EP2040712B1 (en) 2006-07-18 2011-03-02 Anadys Pharmaceuticals, Inc. Carbonate and carbamate prodrugs of thiazolo [4,5-d] pyrimidines
PT2132209E (pt) * 2007-03-19 2014-04-15 Astrazeneca Ab Compostos de 8-oxo-adenina substituídos na posição 9, como moduladores do recetor de tipo ¿toll¿ (tlr7)
PE20081887A1 (es) * 2007-03-20 2009-01-16 Dainippon Sumitomo Pharma Co Nuevo compuesto de adenina
US8466164B2 (en) * 2007-09-14 2013-06-18 Universita Degli Studi Di Siena 4-substituted derivatives of pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine and uses thereof
AU2008323694A1 (en) * 2007-11-07 2009-05-14 Foldrx Pharmaceuticals, Inc. Modulation of protein trafficking
WO2009091032A1 (ja) 2008-01-17 2009-07-23 Dainippon Sumitomo Pharma Co., Ltd. アデニン化合物の製造方法
UY32306A (es) 2008-12-09 2010-07-30 Gilead Sciences Inc Derivados de pteridinona y pirimidinodiazepinona y composiciones farmacéuticas que modulan en forma selectiva los receptores tipo toll, métodos y usos
GB0908772D0 (en) 2009-05-21 2009-07-01 Astrazeneca Ab New salts 756
PL2477987T3 (pl) 2009-09-14 2018-06-29 Gilead Sciences, Inc. Modulatory receptorów toll-podobnych
AU2010310813B2 (en) * 2009-10-22 2015-06-18 Gilead Sciences, Inc. Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections
JP5978226B2 (ja) 2010-12-17 2016-08-24 大日本住友製薬株式会社 プリン誘導体
KR101379808B1 (ko) * 2012-04-03 2014-04-24 울산대학교 산학협력단 산화질소 생성 억제용 피라졸로피리미딘 유도체 화합물
CA2925211A1 (en) * 2013-09-27 2015-04-02 Nimbus Iris, Inc. Irak inhibitors and uses thereof
WO2015137887A1 (en) 2014-03-13 2015-09-17 Agency For Science, Technology And Research Fused pyrimidine-based hydroxamate derivatives
WO2015162075A1 (en) * 2014-04-22 2015-10-29 F. Hoffmann-La Roche Ag 4-amino-imidazoquinoline compounds
EP3190113B1 (en) * 2014-08-15 2021-05-19 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Pyrrolopyrimidine compounds used as tlr7 agonist
CN105367576A (zh) * 2014-08-15 2016-03-02 正大天晴药业集团股份有限公司 作为tlr7激动剂的吡咯并嘧啶化合物
US20170247343A1 (en) 2014-09-11 2017-08-31 Bristol-Myers Squibb Company Thioether triazolopyridine and triazolopyrimidine inhibitors of myeloperoxidase

Also Published As

Publication number Publication date
TW201819387A (zh) 2018-06-01
WO2018095426A1 (zh) 2018-05-31
KR20190084991A (ko) 2019-07-17
MY192084A (en) 2022-07-26
JP2019535730A (ja) 2019-12-12
AU2017366621A1 (en) 2019-05-23
PT3546457T (pt) 2021-08-06
RU2019118390A (ru) 2020-12-28
TWI760390B (zh) 2022-04-11
US20210115046A1 (en) 2021-04-22
EP3546457A4 (en) 2020-05-20
US11117898B2 (en) 2021-09-14
ES2886973T3 (es) 2021-12-21
RU2748833C2 (ru) 2021-05-31
RU2019118390A3 (es) 2020-12-28
EP3546457B1 (en) 2021-07-14
AU2017366621B2 (en) 2021-07-29
MX391180B (es) 2025-03-21
HUE054964T2 (hu) 2021-10-28
JP7145854B2 (ja) 2022-10-03
CN108884092A (zh) 2018-11-23
BR112019010182A2 (pt) 2019-09-17
US20210380593A1 (en) 2021-12-09
EP3546457A1 (en) 2019-10-02
CN108884092B (zh) 2021-06-29
CA3044903A1 (en) 2018-05-31

Similar Documents

Publication Publication Date Title
MX2019005379A (es) Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo.
MX2019001481A (es) Derivado de oxopicolinamida, metodo de preparacion y uso farmaceutico del mismo.
ECSP19010079A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
UY37435A (es) Pirrolidinas sustituidas y métodos para usarlas
MX2020004467A (es) Metodos para el tratamiento o la prevencion del asma mediante la administracion de antagonista de il-4r.
MX2017002028A (es) Compuestos de pirrolopirimidina usados como agonista del receptor de tipo toll 7 (tlr7).
MX372914B (es) Derivado de piperidina y metodo de preparacion y uso farmaceutico del mismo.
CO2017001493A2 (es) Kits que comprenden inhibidores tigit y agentes anticáncer
UY36342A (es) Nuevos derivados de aminoalquilbenzotiazepinas y usos de los mismos
MX2018005708A (es) Compuesto de 7-(tiazol-5-il)pirrolopirimidina como agonista de tlr7.
CL2015003801A1 (es) Formulaciones de anticuerpos y metodos
BR112016012146A2 (pt) Compostos derivados de aminopiridina como inibidores quinase da família tam, composição farmacêutica compreendendo ditos compostos e uso terapêutico dos mesmos
BR112015021888A8 (pt) inibidores de dna-pk, seus usos e composição farmacêutica
MX2016008131A (es) Compuestos heterociclos biciclicos y sus usos en terapia.
BR112015026023A2 (pt) derivados de 2- aminopirido[4,3-d]pirimidin-5-ona e seu uso como inibidores de wee-1
MX2016007410A (es) Derivados del isocromeno como inhibidores de las fosfoinositido-3 cinasas.
EA201691808A8 (ru) Кортикостероидные композиции для местного применения
CL2015002835A1 (es) Nuevos derivados de piridina
DOP2016000253A (es) Nuevos compuestos
BR112016016870A2 (pt) Derivados de icariina, seus usos, e composição farmacêutica
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
DOP2016000007A (es) Pirazolpiridinas sustituidas
MX383254B (es) Combinacion que comprende un glucocorticoide y edo-s101.
CL2019002480A1 (es) Derivados de pirazol como inhibidores de bromodominio.
MX2017013137A (es) Derivados de cromeno como inhibidores de las fosfoinositido-3-cina sas.